Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
View HTML
Toggle Summary Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
View HTML
Toggle Summary Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations HOUSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company
View HTML
Toggle Summary Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Positive initial results from AVB-500 Phase 1b portion of Phase 1b/2 clinical trial in clear cell renal cell carcinoma; expect to initiate Phase 2 trial in second half of 2021 On track to initiate the AVB-500 Phase 1b/2 clinical trial in pancreatic adenocarcinoma in second half of 2021 Achieved
View HTML
Toggle Summary Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
View HTML
Toggle Summary Aravive Achieves Second Development Milestone from 3D Medicines
Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer HOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative
View HTML
Toggle Summary Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
View HTML
Toggle Summary Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma
Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500 HOUSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced positive initial
View HTML
Toggle Summary Aravive Announces Three New Appointments to its Board of Directors
Further Strengthens Senior Executive Leadership Team HOUSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the appointments of John A. Hohneker, M.D., Sigurd C.
View HTML
Toggle Summary Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer First patient dosed in registrational Phase 3 trial of AVB-500 in platinum resistant ovarian cancer; on track to conduct interim analysis in first
View HTML